Mundipharma reported that data from Janssen's late-stage trial of Invokana, or canagliflozin, showed that use of the treatment resulted in a 30% decrease in the risk of renal failure, kidney transplant or dialysis, as well as cardiovascular or renal death, in patients with chronic kidney disease who also have type II diabetes. The drug was so efficient that the CREDENCE trial was halted early in July due to its efficacy in an international cohort of over 4,400 adults with type II diabetes from 34 countries across 659 sites.